Clinical Trial

A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy

Name: A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy — clinical trial record (NCT07752264)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is an open-label, single-arm Phase I/II clinical study to evaluate the efficacy and safety of Eque-cel Injection in patients with refractory immune-mediated necrotizing myopathy.

Trial Details

NCT Number	NCT07752264
Lead Sponsor	Nanjing IASO Biotechnology Co., Ltd.
Conditions	Refractory Immune-mediated Necrotizing Myopathy
Enrollment	27 participants
Start Date	2026-08-15
Primary Completion	2030-08-15 (estimated)
Study Completion	2043-08-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-07